Bisoprolol
Zebeta, Ziac (bisoprolol) is a small molecule pharmaceutical. Bisoprolol was first approved as Zebeta on 1992-07-31. It is used to treat angina pectoris, heart failure, hypertension, myocardial infarction, and supraventricular tachycardia in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Combinations
Ziac (generic drugs available since 2000-09-25)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| bisoprolol fumarate and hydrochlorothiazide | NDA authorized generic | 2023-05-19 |
| ziac | New Drug Application | 2021-05-18 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| angina pectoris | EFO_0003913 | D000787 | I20 |
| heart failure | EFO_0003144 | D006333 | I50 |
| hypertension | EFO_0000537 | D006973 | I10 |
| myocardial infarction | EFO_0000612 | D009203 | I21 |
| supraventricular tachycardia | HP_0004755 | D013617 | I47.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C07: Beta-adrenergic blocking agents
— C07A: Beta blocking agents
— C07AB: Beta blocking agents, selective
— C07AB07: Bisoprolol
— C07B: Beta blocking agents and thiazides
— C07BB: Beta blocking agents, selective, and thiazides
— C07BB07: Bisoprolol and thiazides
— C07F: Beta blocking agents, other combinations
— C07FB: Beta blocking agents and calcium channel blockers
— C07FB07: Bisoprolol and amlodipine
— C07FX: Beta blocking agents, other combinations
— C07FX04: Bisoprolol and acetylsalicylic acid
— C09: Agents acting on the renin-angiotensin system
— C09B: Ace inhibitors, combinations
— C09BX: Ace inhibitors, other combinations in atc
— C09BX02: Perindopril and bisoprolol
— C09BX04: Perindopril, bisoprolol and amlodipine
— C09BX05: Ramipril and bisoprolol
HCPCS
No data
Clinical
Clinical Trials
35 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | 3 | — | 1 | 4 |
| Adrenoleukodystrophy | D000326 | Orphanet_43 | E71.52 | — | 1 | 1 | — | — | 1 |
| Asthma | D001249 | EFO_0000270 | J45 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 5 | 1 | — | — | 1 | 7 | ||
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | — | 2 | — | — | — | 2 |
| Huntington disease | D006816 | G10 | — | 1 | — | — | — | 1 | |
| Motor neuron disease | D016472 | EFO_0003782 | G12.2 | — | 1 | — | — | — | 1 |
| Peripheral nervous system diseases | D010523 | G64 | — | 1 | — | — | — | 1 | |
| Chronic inflammatory demyelinating polyradiculoneuropathy | D020277 | EFO_1000868 | G61.81 | — | 1 | — | — | — | 1 |
| Charcot-marie-tooth disease | D002607 | G60.0 | — | 1 | — | — | — | 1 | |
| Myelodysplastic syndromes | D009190 | D46 | — | 1 | — | — | — | 1 | |
| Myeloid leukemia acute | D015470 | C92.0 | — | 1 | — | — | — | 1 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 2 | 2 |
| Thoracic diseases | D013896 | — | — | — | — | 1 | 1 | ||
| Parathyroid diseases | D010279 | E21.5 | — | — | — | — | 1 | 1 | |
| Depression | D003863 | F33.9 | — | — | — | — | 1 | 1 | |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | — | — | — | 1 | 1 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | — | 1 | 1 |
| Restless legs syndrome | D012148 | EFO_0004270 | G25.81 | — | — | — | — | 1 | 1 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | — | — | — | 1 | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BISOPROLOL |
| INN | bisoprolol |
| Description | Bisoprolol is a secondary alcohol and a secondary amine. It has a role as an antihypertensive agent, a beta-adrenergic antagonist, an anti-arrhythmia drug and a sympatholytic agent. |
| Classification | Small molecule |
| Drug class | beta-blockers (propranolol type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 66722-44-9 |
| RxCUI | 19484 |
| ChEMBL ID | CHEMBL645 |
| ChEBI ID | 3127 |
| PubChem CID | 2405 |
| DrugBank | DB00612 |
| UNII ID | Y41JS2NL6U (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,821 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
618 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more